NORTHWEST BIOTHERAPEUTICS INC (NWBO)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Northwest Biotherapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | 0.1321 | 0.1390 | 0.1222 | 0.1319 | 3,998,398 |
| Nov 19, 2026 | 0.1442 | 0.1500 | 0.1350 | 0.1390 | 5,147,986 |
| Nov 18, 2026 | 0.1500 | 0.1573 | 0.1440 | 0.1451 | 3,643,198 |
| Nov 17, 2026 | 0.1480 | 0.1528 | 0.1362 | 0.1461 | 6,363,405 |
| Nov 16, 2026 | 0.1599 | 0.1599 | 0.1451 | 0.1462 | 4,437,443 |
| Nov 13, 2026 | 0.1651 | 0.1660 | 0.1550 | 0.1565 | 4,764,574 |
| Nov 12, 2026 | 0.1691 | 0.1711 | 0.1641 | 0.1651 | 2,819,582 |
| Nov 11, 2026 | 0.1660 | 0.1685 | 0.1636 | 0.1684 | 1,477,526 |
| Nov 10, 2026 | 0.1682 | 0.1685 | 0.1621 | 0.1668 | 1,504,625 |
| Nov 9, 2026 | 0.1689 | 0.1698 | 0.1626 | 0.1669 | 4,661,507 |
| Nov 6, 2026 | 0.1699 | 0.1699 | 0.1620 | 0.1665 | 4,304,179 |
| Nov 5, 2026 | 0.1700 | 0.1718 | 0.1601 | 0.1648 | 7,316,281 |
| Nov 4, 2026 | 0.1710 | 0.1846 | 0.1571 | 0.1650 | 8,110,834 |
| Nov 3, 2026 | 0.1745 | 0.1758 | 0.1675 | 0.1692 | 2,182,414 |
| Nov 2, 2026 | 0.1720 | 0.1768 | 0.1600 | 0.1759 | 3,249,850 |
| Oct 30, 2026 | 0.1684 | 0.1774 | 0.1660 | 0.1700 | 3,080,258 |
| Oct 29, 2026 | 0.1684 | 0.1699 | 0.1651 | 0.1685 | 3,977,536 |
| Oct 28, 2026 | 0.1615 | 0.1700 | 0.1615 | 0.1668 | 2,299,920 |
| Oct 27, 2026 | 0.1689 | 0.1700 | 0.1610 | 0.1615 | 5,926,225 |
| Oct 26, 2026 | 0.1543 | 0.1695 | 0.1470 | 0.1675 | 7,638,072 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CHIEF SCIENTIFIC OFFICER | Withholding/Transfer | 1.00M | -- | Aug 29, 2024 | |
| Director | Sale | 150.0K | $123.5K | Nov 17, 2023 | |
| Director | Sale | 295.0K | $241.6K | Nov 17, 2023 | |
| Director | Sale | 125.0K | $104.4K | Nov 16, 2023 | |
| CHIEF SCIENTIFIC OFFICER | Withholding/Transfer | 6.79M | -- | Apr 4, 2023 |
| Name | Shares | % | Source |
|---|---|---|---|
COMPASS FINANCIAL MANAGEMENT LLC | 1.6M | 0.1% | 13F |
BOSCH MARNIX L Chief Technical Officer | 119.4K | 0.0% | FORM 4 |
Opus Capital Group, LLC | 60.1K | 0.0% | 13F |
Ethos Financial Group, LLC | 39.1K | 0.0% | 13F |
Williams Jones Wealth Management, LLC. | 25.0K | 0.0% | 13F |
Markowski Investments | 1.1K | 0.0% | 13F |
HANTZ FINANCIAL SERVICES, INC. | 250 | 0.0% | 13F |
Insiders
- BOYNTON ALTON LCHIEF SCIENTIFIC OFFICER
- MALIK NAVIDDirector
- BOSCH MARNIX LChief Technical Officer
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells.
The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer.
Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
based on 1.81B shares outstanding
30d Avg
4.43M
60d Avg
4.90M
90d Avg
4.50M
Signal8's dilution snapshot of NWBO as of Sep 30, 2026 records an effective S-3 shelf registration (effective Nov 25, 2025), 1 outstanding warrant series and an offering closed Sep 8, 2026, from SEC filings. Northwest Biotherapeutics Inc. (OTC: NWBO) traded at $0.1319 on Nov 20, 2026, down 5.11% from the previous close of $0.1390. 52-week range: $0.1222 to $0.3389. The company is in the Healthcare sector (Biotechnology).